Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

Katsumasa Kuroi, Kojiro Shimozuma, Yasuo Ohashi, Kazufumi Hisamatsu, Norikazu Masuda, Ayano Takeuchi, Toshihiko Aranishi, Satoshi Morita, Shozo Ohsumi, Frederick H. Hausheer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Goals of work The aim of this study was to prospectively evaluate chemotherapy-induced peripheral neuropathy (CIPN) using a patient-based instrument, the Patient Neurotoxicity Questionnaire (PNQ) and a physician-based instrument, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) in patients with advanced or metastatic breast cancer who were treated with weekly paclitaxel. Materials and methods CIPN symptoms were prospectively assessed in 35 patients using the PNQ, NCI-CTC, and the Functional Assessment of Cancer Therapy (FACT)-Taxane including neurotoxicity component (Ntx) at the baseline, and 8 and 16 weeks after starting chemotherapy. Results For sensory neuropathy symptoms, the reported incidence of CIPN was significantly increased during active treatment in terms of both the PNQ and NCI-CTC assessments. In contrast, there was a notable increase of patient motor neuropathy symptoms that were elucidated only by the PNQ. The PNQ grades of CIPN were widely distributed in the patient population as compared with the NCI-CTC grades for both sensory and motor neuropathy. The sensory PNQ grade was correlated with sensory NCI-CTC grade (r=0.58) and Ntx (r=0.51), and the motor PNQ grade was correlated with Ntx (r=0.57). Conclusions The PNQ appears to be more sensitive and responsive than the NCI-CTC for CIPN; the PNQ appears to have diagnostic validity for evaluating CIPN in patients who are receiving neurotoxic chemotherapy.

Original languageEnglish
Pages (from-to)1071-1080
Number of pages10
JournalSupportive Care in Cancer
Volume17
Issue number8
DOIs
Publication statusPublished - 2009 Aug
Externally publishedYes

Fingerprint

Peripheral Nervous System Diseases
Paclitaxel
Breast Neoplasms
Drug Therapy
National Cancer Institute (U.S.)
Surveys and Questionnaires

Keywords

  • Breast cancer
  • Chemotherapy
  • Neurotoxicity
  • Paclitaxel
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Oncology

Cite this

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). / Kuroi, Katsumasa; Shimozuma, Kojiro; Ohashi, Yasuo; Hisamatsu, Kazufumi; Masuda, Norikazu; Takeuchi, Ayano; Aranishi, Toshihiko; Morita, Satoshi; Ohsumi, Shozo; Hausheer, Frederick H.

In: Supportive Care in Cancer, Vol. 17, No. 8, 08.2009, p. 1071-1080.

Research output: Contribution to journalArticle

Kuroi, Katsumasa ; Shimozuma, Kojiro ; Ohashi, Yasuo ; Hisamatsu, Kazufumi ; Masuda, Norikazu ; Takeuchi, Ayano ; Aranishi, Toshihiko ; Morita, Satoshi ; Ohsumi, Shozo ; Hausheer, Frederick H. / Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). In: Supportive Care in Cancer. 2009 ; Vol. 17, No. 8. pp. 1071-1080.
@article{6005c6a47ab64445aa7120a25fc628a6,
title = "Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)",
abstract = "Goals of work The aim of this study was to prospectively evaluate chemotherapy-induced peripheral neuropathy (CIPN) using a patient-based instrument, the Patient Neurotoxicity Questionnaire (PNQ) and a physician-based instrument, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) in patients with advanced or metastatic breast cancer who were treated with weekly paclitaxel. Materials and methods CIPN symptoms were prospectively assessed in 35 patients using the PNQ, NCI-CTC, and the Functional Assessment of Cancer Therapy (FACT)-Taxane including neurotoxicity component (Ntx) at the baseline, and 8 and 16 weeks after starting chemotherapy. Results For sensory neuropathy symptoms, the reported incidence of CIPN was significantly increased during active treatment in terms of both the PNQ and NCI-CTC assessments. In contrast, there was a notable increase of patient motor neuropathy symptoms that were elucidated only by the PNQ. The PNQ grades of CIPN were widely distributed in the patient population as compared with the NCI-CTC grades for both sensory and motor neuropathy. The sensory PNQ grade was correlated with sensory NCI-CTC grade (r=0.58) and Ntx (r=0.51), and the motor PNQ grade was correlated with Ntx (r=0.57). Conclusions The PNQ appears to be more sensitive and responsive than the NCI-CTC for CIPN; the PNQ appears to have diagnostic validity for evaluating CIPN in patients who are receiving neurotoxic chemotherapy.",
keywords = "Breast cancer, Chemotherapy, Neurotoxicity, Paclitaxel, Peripheral neuropathy",
author = "Katsumasa Kuroi and Kojiro Shimozuma and Yasuo Ohashi and Kazufumi Hisamatsu and Norikazu Masuda and Ayano Takeuchi and Toshihiko Aranishi and Satoshi Morita and Shozo Ohsumi and Hausheer, {Frederick H.}",
year = "2009",
month = "8",
doi = "10.1007/s00520-008-0550-x",
language = "English",
volume = "17",
pages = "1071--1080",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

AU - Kuroi, Katsumasa

AU - Shimozuma, Kojiro

AU - Ohashi, Yasuo

AU - Hisamatsu, Kazufumi

AU - Masuda, Norikazu

AU - Takeuchi, Ayano

AU - Aranishi, Toshihiko

AU - Morita, Satoshi

AU - Ohsumi, Shozo

AU - Hausheer, Frederick H.

PY - 2009/8

Y1 - 2009/8

N2 - Goals of work The aim of this study was to prospectively evaluate chemotherapy-induced peripheral neuropathy (CIPN) using a patient-based instrument, the Patient Neurotoxicity Questionnaire (PNQ) and a physician-based instrument, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) in patients with advanced or metastatic breast cancer who were treated with weekly paclitaxel. Materials and methods CIPN symptoms were prospectively assessed in 35 patients using the PNQ, NCI-CTC, and the Functional Assessment of Cancer Therapy (FACT)-Taxane including neurotoxicity component (Ntx) at the baseline, and 8 and 16 weeks after starting chemotherapy. Results For sensory neuropathy symptoms, the reported incidence of CIPN was significantly increased during active treatment in terms of both the PNQ and NCI-CTC assessments. In contrast, there was a notable increase of patient motor neuropathy symptoms that were elucidated only by the PNQ. The PNQ grades of CIPN were widely distributed in the patient population as compared with the NCI-CTC grades for both sensory and motor neuropathy. The sensory PNQ grade was correlated with sensory NCI-CTC grade (r=0.58) and Ntx (r=0.51), and the motor PNQ grade was correlated with Ntx (r=0.57). Conclusions The PNQ appears to be more sensitive and responsive than the NCI-CTC for CIPN; the PNQ appears to have diagnostic validity for evaluating CIPN in patients who are receiving neurotoxic chemotherapy.

AB - Goals of work The aim of this study was to prospectively evaluate chemotherapy-induced peripheral neuropathy (CIPN) using a patient-based instrument, the Patient Neurotoxicity Questionnaire (PNQ) and a physician-based instrument, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) in patients with advanced or metastatic breast cancer who were treated with weekly paclitaxel. Materials and methods CIPN symptoms were prospectively assessed in 35 patients using the PNQ, NCI-CTC, and the Functional Assessment of Cancer Therapy (FACT)-Taxane including neurotoxicity component (Ntx) at the baseline, and 8 and 16 weeks after starting chemotherapy. Results For sensory neuropathy symptoms, the reported incidence of CIPN was significantly increased during active treatment in terms of both the PNQ and NCI-CTC assessments. In contrast, there was a notable increase of patient motor neuropathy symptoms that were elucidated only by the PNQ. The PNQ grades of CIPN were widely distributed in the patient population as compared with the NCI-CTC grades for both sensory and motor neuropathy. The sensory PNQ grade was correlated with sensory NCI-CTC grade (r=0.58) and Ntx (r=0.51), and the motor PNQ grade was correlated with Ntx (r=0.57). Conclusions The PNQ appears to be more sensitive and responsive than the NCI-CTC for CIPN; the PNQ appears to have diagnostic validity for evaluating CIPN in patients who are receiving neurotoxic chemotherapy.

KW - Breast cancer

KW - Chemotherapy

KW - Neurotoxicity

KW - Paclitaxel

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=75149198437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149198437&partnerID=8YFLogxK

U2 - 10.1007/s00520-008-0550-x

DO - 10.1007/s00520-008-0550-x

M3 - Article

C2 - 19089463

AN - SCOPUS:75149198437

VL - 17

SP - 1071

EP - 1080

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 8

ER -